BioSpace News Archive

BBI Solutions demonstrated how its pioneering point of care testing enables users to securely read, interpret and transmit rapid assay results at the world’s largest laboratory medicine tradeshow, the American Association for Clinical Chemistry annual conference.

Pre-Application Letters of Intent are Due September 13 for the 2019-2020 Funding Cycle

The FDA approved Rozlytrek for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer. Also, Rozlytrek secured accelerated approval for the treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy.

Current rules set by the FDA allow companies to assess whether or not long-term follow-ups are required based on risk factors determined by the company.

Although some of the top-selling drugs in the world are facing patent cliffs between now and then, many of them are still projected to continue being big sellers between now and 2024.

The U.S. Food and Drug Administration approved Impact’s Inrebic for the treatment for adult patients with certain types of myelofibrosis, cancers of the bone marrow.

The researchers are currently optimizing the drug and similar drugs so they can advance to human clinical trials.

Auris Medical Holding Ltd. provided a business update and announced financial results for the first half of the 2019 financial year ended June 30, 2019.

The device is most likely to be used in optogenetics, where light is used to stimulate cellar activity. It may also have functionality for monitoring tissues and cells during medical procedures.

When it comes to potential pricing controls of the pharmaceutical industry, Jim Greenwood, chief executive officer of BIO, grimly stated that “nothing good” was going on in the halls of power in Washington, D.C.